Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804648 | 0.93 | THRB (0.36) | PTGDR2THRBHTR2ATSHRPTGDR | |
| SCHEMBL19796399 | 0.82 | SCN9A (0.38) | THRBHTR2ATSHR | |
| SCHEMBL19804011 | 0.81 | THRB (0.41) | PTGDR2THRBTSHRPTGDRPTGER2 | |
| SCHEMBL19940069 | 0.80 | PTGDR2 (0.46) | PTGDR2THRBTSHRPTGDRPTGER2 | |
| SCHEMBL19804488 | 0.79 | THRB (0.38) | PTGDR2THRBTSHRPTGDRALDH1A1 | |
| SCHEMBL19804550 | 0.76 | THRB (0.37) | THRBTSHRALDH1A1TP53HIF1A | |
| SCHEMBL19804649 | 0.75 | THRB (0.38) | PTGDR2THRBTSHRALDH1A1TP53 | |
| SCHEMBL19804569 | 0.75 | FFAR4 (0.42) | PTGDR2THRBTSHR | |
| SCHEMBL19804428 | 0.74 | FFAR4 (0.40) | THRBSLC6A9 | |
| SCHEMBL19804588 | 0.74 | PPARG (0.38) | PTGDR2THRBPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | PTGDR2 2110/4885THRB 4323/4885HTR2A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.